Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visilizumab in moderate to severe Crohn's disease
ISRCTN16473514Phase 2Completed
- Sponsor
- PDL BioPharma
- Start
- Oct 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of visilizumab in Crohn's disease, sponsored by PDL BioPharma. Primary endpoint: Clinical activity. Started Oct 2004; status: completed.
02
Drugs
visilizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ISRCTN16473514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16473514.